Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
…, A Fraser, PM Irving, N Kamperidis, KB Kok… - Gut, 2021 - gut.bmj.com
Objective Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for
a lower level of immunity across more of the population. We investigated whether patients …
a lower level of immunity across more of the population. We investigated whether patients …
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab …
…, AL Hart, PM Irving, GR Jones, KB Kok… - Nature …, 2022 - nature.com
Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection
and impair protective immunity following pneumococcal and influenza vaccination. Here we …
and impair protective immunity following pneumococcal and influenza vaccination. Here we …
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
Objective Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …
[HTML][HTML] Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease
…, AR Greenplate, KL Soring, GR Corazza, KB Kok… - Gastroenterology, 2015 - Elsevier
Background & Aims Many patients with inflammatory bowel disease (IBD) fail to respond to
anti–tumor necrosis factor (TNF) agents such as infliximab and adalimumab, and etanercept …
anti–tumor necrosis factor (TNF) agents such as infliximab and adalimumab, and etanercept …
Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients
…, H Ibraheim, P Kelleher, KB Kok… - Journal of Crohn's …, 2022 - academic.oup.com
Background and Aims Infliximab attenuates serological responses to SARS-CoV-2 infection.
Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences …
Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences …
[HTML][HTML] A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE) …
…, PM Irving, M Johnson, AJ Kent, KB Kok… - The Lancet …, 2024 - thelancet.com
Background Management strategies and clinical outcomes vary substantially in patients newly
diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker …
diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker …
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
…, C Auckland, LW Harries, M Davies, S Michell, KB Kok… - Gut, 2023 - gut.bmj.com
Objective Antitumour necrosis factor (TNF) drugs impair serological responses following
SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-…
SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-…
Fecal calprotectin in gastrointestinal disease
J Murray, KB Kok, RM Ayling - Clinical Chemistry, 2023 - academic.oup.com
Background Inflammatory bowel disease (IBD) comprises a group of chronic conditions
characterized by relapsing and remitting inflammation of the gastrointestinal tract. The incidence …
characterized by relapsing and remitting inflammation of the gastrointestinal tract. The incidence …
[HTML][HTML] Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients
To inform healthcare policy for immunosuppressed patients there is a need to define SARS-CoV-2
vaccine responses. Here we report SARS-CoV-2 vaccine-induced antibody and T cell …
vaccine responses. Here we report SARS-CoV-2 vaccine-induced antibody and T cell …
Provision of care for pregnant women with IBD in the UK: the current landscape
S Wolloff, E Moore, T Glanville, J Limdi, KB Kok… - Frontline …, 2021 - fg.bmj.com
Introduction Suboptimal control of inflammatory bowel disease (IBD) can result in increased
rates of adverse pregnancy-related outcomes. We aimed to describe the current landscape …
rates of adverse pregnancy-related outcomes. We aimed to describe the current landscape …
